In a blow to its obesity pipeline, Pfizer drops danuglipron after liver injury case
Pfizer has discontinued its once-daily obesity pill danuglipron after a patient in one of its clinical trials had a liver injury that may have been drug-induced. A Pfizer spokesperson told Endpoints News that the case ...
